

Patient	Specimen	Account
Patient Name: Jane Doe Date of Birth: 02-22-1952 MRN/Patient #: 1234-1	Specimen #: 123-456-789 Collection Date: 03-11-2024 Received Date: 03-12-2024 Report Date: 03-14-2024 Specimen Type: Clean catch urine Mdxhealth Accession #: A00000	Physician: Dr. Smith Account: Urology Care Address: 12345 Alton City, State, Zip: Irvine, CA 92618

PATIENT RESULT: PATHOGEN(S) DETECTED

Pathogen(s) Detected

Pathogen(s) Detected	CFU/ml
Enterococcus faecalis	4.36 x 10 ⁶
Escherichia coli	9.56 x 10 ⁵

Resistance Gene(s) Detected

Resistance Gene(s) Detected	Antimicrobial Resistance
Trimethoprim/Sulfamethoxazole	Trimethoprim-sulfamethoxazole

Patient Susceptible Antimicrobials

- Fosfomycin PO
- Nitrofurantoin PO
- Amoxicillin-clavulanate PO
- Minocycline PO/IV
- Moxifloxacin PO/IV
- Tetracycline PO/IV
- Doxycycline PO/IV
- Ampicillin PO/IM/IV
- Ampicillin-sulbactam IV
- Piperacillin-tazobactam IV

Patient Susceptibility Report

Report Key

S = Susceptible **I = Intermediate** **R = Resistant**

SDD = Susceptible-Dose Dependent ***R = Data not patient specific**

N/A = Detected organism has variable results **SNP = Susceptibility not performed**

Antimicrobial	Formulation	Antimicrobial Phenotypic Susceptibility	Supportive Data (not patient specific)	
			Escherichia coli	Enterococcus faecalis
Amoxicillin-clavulanate	PO	S	✓	✓
Fosfomycin	PO	S	✓	✓
Nitrofurantoin	PO	S	✓	✓
Doxycycline	PO/IV	S	✓	✓
Minocycline	PO/IV	S	✓	✓
Moxifloxacin	PO/IV	S	✓	✓
Tetracycline	PO/IV	S	✓	✓
Ampicillin	PO/IM/IV	S	✓	✓
Ampicillin-sulbactam	IV	S	✓	✓
Piperacillin-tazobactam	IV	S	✓	✓
Levofloxacin	PO/IV	I	✓	✓
Cefaclor	PO	R		✓
Cefdinir	PO	R		✓

Antimicrobial	Formulation	Antimicrobial Phenotypic Susceptibility	Supportive Data (not patient specific)	
			Escherichia coli	Enterococcus faecalis
Cephalexin	PO	R		✓
Linezolid	PO	R	✓	
Ciprofloxacin	PO/IV	R	✓	✓
Trimethoprim-sulfamethoxazole	PO/IV	R		✓
Cefazolin	IM/IV	R		✓
Cefepime	IM/IV	R		✓
Cefoxitin	IM/IV	R		✓
Ceftriaxone	IM/IV	R		✓
Gentamicin	IM/IV	R	✓	✓
Aztreonam	IV	R		✓
Vancomycin	IV	R	✓	
Ofloxacin	PO/IM/IV	N/A	✓	✓
Meropenem	IV	N/A	✓	✓

COMMENT:

N/A

RESISTANCE GENE(S) - NOT DETECTED:

Carbapenem (CRE) Resistant, Extended Spectrum Beta-Lactamase (ESBL), Fluoroquinolone, Methicillin Resistance (*mecA*), Vancomycin Resistant (VRE)

PATHOGEN(S) - NOT DETECTED:**BACTERIA:**

- *Acinetobacter baumannii*
- *Citrobacter freundii*
- *Citrobacter koseri*
- *Enterobacter cloacae*
- *Enterococcus faecium*
- *Klebsiella aerogenes*
- *Klebsiella oxytoca*
- *Klebsiella pneumoniae*
- *Morganella morganii*
- *Proteus mirabilis*
- *Pseudomonas aeruginosa*
- *Serratia marcescens*
- *Staphylococcus aureus*
- *Staphylococcus epidermidis*
- *Staphylococcus saprophyticus*
- *Streptococcus pyogenes*

YEAST:

- *Candida albicans*

Information About the Patient Susceptibility Report:

Gray checkmarks indicate there is supportive evidence that the antibiotic, either FDA approved or off label, can be used for treatment. Treatment options are not intended to be prescriptive for any specific patient. Appropriate medical judgment should be exercised by the attending physician before prescribing a course of treatment.

Methodology and Clinical Significance:

Pathogens and Resistance Genes are detected through real time multiplex PCR. Pathogens are quantified based on cells per milliliter of urine based on the following limit of detection: *Candida albicans* (1×10^3), *Acinetobacter baumannii* (1×10^3), *Citrobacter freundii* (1×10^3), *Citrobacter koseri* (1×10^3), *Enterobacter cloacae* (1×10^3), *Enterococcus faecalis* (1×10^3), *Enterococcus faecium* (1×10^4), *Escherichia coli* (1×10^3), *Klebsiella aerogenes* (1×10^3), *Klebsiella oxytoca* (1×10^3), *Klebsiella pneumoniae* (1×10^3), *Morganella morganii* (1×10^3), *Proteus mirabilis* (1×10^3), *Pseudomonas aeruginosa* (1×10^3), *Serratia marcescens* (1×10^3), *Staphylococcus aureus* (1×10^4), *Staphylococcus epidermidis* (1×10^3), *Staphylococcus saprophyticus* (1×10^3), *Streptococcus pyogenes* (1×10^3). Resistance genes are reported as “detected” or “not detected.” Antimicrobial susceptibility is determined by testing the whole urine polymicrobial population against a panel of antimicrobial agents.

Disclaimer:

Mdxhealth is regulated under the Clinical Laboratory Improvement Amendments (CLIA) as an accredited laboratory to perform high complexity clinical testing. The Resolve mdx test was developed, and its performance characteristics determined by mdxhealth. It has not been cleared or approved by the US Food and Drug Administration. The FDA has determined such clearance or approval is not necessary. Use outside of this indication has not been validated by mdxhealth. Test results should be interpreted in conjunction with other laboratory and clinical data available to the clinician and relevant guidelines on the decision for Urinary Tract Infection.

This test was performed by Delta Laboratories LLC dba mdxhealth Central, 7000 Preston Road, Suite 1500, Plano, TX 75024.
CLIA# 45D2229819; CAP# 9356578.

Joseph L. Sailors, M.D.

Joseph L. Sailors, MD, Laboratory Director



mdxhealth®